| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
7 |
| Employees |
19 |
| Revenues (TTM) (Millions $) |
20 |
| Net Income (TTM) (Millions $) |
-16 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
We are a womens healthcare firm devoted to meeting todays womens unmet health requirements. We have stayed strong in our commitment to innovate in womens healthcare, where there are still unmet needs not only in contraception, but also in other important therapeutic areas for womens health.
Twirla is our first product, a once-weekly prescription hormonal contraceptive patch. It gives an estrogen dosage that is comparable to that of routinely prescribed combination hormonal contraceptives, or CHCs, and is lower than that of other commercially available contraceptive patches. We think there is a market for a contraceptive patch that delivers about 30 mcg of estrogen and 120 mcg of progestin in a convenient dose form that can help with noninvasive compliance. Twirla uses Skinfusion', our own patented transdermal patch technology. Skinfusion is aimed to distribute drugs via the skin while improving patch adherence, patient comfort, and wearability, all of which may aid compliance.
Other than sterilization, contraceptive techniques can be split into non-hormonal and hormonal options. The diaphragm, male condom, female condom, and non-hormonal intrauterine device, or IUD, are all non-hormonal products available in the United States. CHCs are hormonal contraceptives that include both estrogen and a progestin, and P-only contraceptives are those that contain just progestin.
Twirla is our first and only authorized product, and weve spent nearly all of our resources to date acquiring Twirlas approval and launching Twirlas commercialization. We put our pipeline on hold while we waited for Twirlas clearance and prepared for commercial launch. Weve started a thorough review of our pipeline in order to devise a strategy for moving forward with Twirla line extensions and other possible product candidates.
Company Address: 500 College Road East, Suite 300 Princeton 8540 NJ
Company Phone Number: 683-1880 Stock Exchange / Ticker: AGRX
|
%
2.29%